Compstatin and analogs thereof for eye disorders

A technology for eye diseases and analogs, which can be used in medical preparations containing active ingredients, metabolic diseases, drug combinations, etc., and can solve problems such as limited treatment options for ARMD

Active Publication Date: 2008-12-17
APELLIS PHARMA
View PDF36 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Treatment options for ARMD are limited, and none are completely effective (Ambati, J. et al., Ophthalmic Survey, 48(3):257-293, 2003, and references therein)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compstatin and analogs thereof for eye disorders
  • Compstatin and analogs thereof for eye disorders
  • Compstatin and analogs thereof for eye disorders

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0089] overview

[0090] The present invention provides compositions and methods for treating ocular disorders characterized by macular degeneration, choroidal neovascularization, retinal neovascularization, ocular inflammation, or any combination of the foregoing. The phrase "characterized by" is intended to indicate that macular degeneration, CNV, RNV and / or ocular inflammation are characteristic (ie typical) features of the disorder. Macular degeneration, CNV, RNV and / or ocular inflammation can be defining and / or diagnostic properties of the condition. Exemplary conditions that are characterized by one or more of these properties and that can be treated with the compositions and methods of the invention include, but are not limited to, conditions associated with macular degeneration, diabetic retinopathy, retinopathy of prematurity, proliferative vitreoretinopathy, ocular Uveitis, keratitis and scleritis. As mentioned above, macular degeneration refers to various degenera...

example 1

[0309] Example 1: Prevention of Choroidal Neovascularization in a Mouse Model by Administration of Compstatin Analogs

[0310] Materials and methods

[0311] complement inhibitor

[0312] Recombinant VCP was produced in and purified from the Pichia pastoris expression system as described (Sahu, A et al., J. Immunol. 160, 5596-5604, 1998). VCP was dissolved in physiological saline at various concentrations.

[0313] figure 2 Compstatin analogs shown in were chemically synthesized and dissolved in saline with positions 4 and 9 altered relative to the compstatin peptide.

[0314] CNV induction in mice

[0315] C57BL / 6 mice (Jackson Laboratory) were anesthetized with a ketamine / xylazine (8:1) mixture and the pupils were dilated with a single drop of 1% tropicamide. Krypton red laser coagulation (50-μm spot size, 0.05 s duration, 250 mW) can be used to generate a laser spot around the optic nerve by using a hand-held coverslip as a contact lens. Bubble formation at the...

example 2

[0331] Example 2: Prevention of Choroidal Neovascularization in a Mouse Model by Administration of Compstatin Analogs

[0332] Example 1 was repeated using different compstatin analogs. Doses of 0.1-50 μg / eye were tested.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

Description

[0001] Related Application Cross-References [0002] This application claims priority over USSN 60 / 725,484, filed October 8, 2005, USSN 60 / 726,447, filed October 12, 2005, and USSN 60 / 726,447, filed January 19, 2006 USSN 60 / 760,974 and claims the benefit of the provisional applications, all of which are incorporated herein by reference. technical field Background technique [0003] The macula is a small area in the retina of the eye, about 3 to 5 mm in size, adjacent to the optic nerve. It is the most sensitive area of ​​the retina and contains the fovea, a depressed area that allows high visual acuity and contains a dense concentration of cones, the photoreceptors responsible for color vision. [0004] The term macular degeneration refers to a number of different diseases characterized by degenerative changes in the macula, all of which can lead to loss of central vision. Age-related macular degeneration (ARMD) is the most common cause of functional blindness in develope...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/08A61K38/10A61P27/02
CPCA61K9/0048A61K9/06A61K38/12A61K45/06A61K47/42C07K14/47C07K2319/01A61K2300/00A61K9/0051C07K7/08C07K14/78G01N33/5088A61K38/00A61P27/02A61P27/06A61P29/00A61P35/00A61P43/00A61P9/10A61P3/10
Inventor 帕斯卡尔·德沙特莱保罗·奥尔森塞德里克·弗朗索瓦
Owner APELLIS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap